行情

AFMD

AFMD

Affimed
NASDAQ

实时行情|Nasdaq Last Sale

3.280
+0.010
+0.31%
盘后: 3.310 +0.03 +0.91% 17:23 05/16 EDT
开盘
3.240
昨收
3.270
最高
3.410
最低
3.220
成交量
86.62万
成交额
0
52周最高
9.82
52周最低
2.880
市值
4.79亿
市盈率(TTM)
-6.0584
分时
5日
1月
3月
1年
5年
Affimed Presents Data on Innate Cell Engagers AFM24 and AFM28 at 19th Meeting of the Society for Natural Immunity
Correlative science data from AFM24-101 clinical study support the rationale to develop AFM24 as monotherapy and in combination therapiesFirst preclinical data set on the combination of AFM28 with natural killer cells, both in co-administration or pre-comp...
GlobeNewswire · 12小时前
What Percentage Of Affimed N.V. (NASDAQ:AFMD) Shares Do Insiders Own?
If you want to know who really controls Affimed N.V. ( NASDAQ:AFMD ), then you'll have to look at the makeup of its...
Simply Wall St. · 2天前
Affimed to Present Preclinical Data Demonstrating Cytotoxic Activity of its Novel Innate Cell Engager AFM28 at the Annual Meeting of the European Hematology Association (EHA)
The novel bispecific innate cell engager AFM28 stimulates NK cells to destroy CD123-positive tumor cells via antibody-dependent cellular cytotoxicity.AFM28 induces effective lysis of hematological tumor cells even at low-levels of CD123 expression; leukemi...
GlobeNewswire · 4天前
BRIEF-Affimed Provides Update On Asco Afm13-104 Oral Presentation
reuters.com · 05/06 20:34
Affimed Reports American Society Of Clinical Oncology Informed Co.'s Collaborator For AFM13-104 It Removed Oral Presentation From Upcoming Conference Program
Affimed N.V. (NASDAQ:AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that the
Benzinga · 05/06 20:04
Affimed Provides Update on ASCO AFM13-104 Oral Presentation
HEIDELBERG, Germany, May 06, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that the Ameri...
GlobeNewswire · 05/06 20:02
BRIEF-Affimed Announces Clinical Update And Trial In Progress Posters At The Annual Meeting Of The American Society Of Clinical Oncology
reuters.com · 04/27 21:40
BRIEF-Affimed Announces Clinical Update And Trial In Progress Posters At The Annual Meeting Of The American Association For Cancer Research (ASCO)
reuters.com · 04/27 21:40
更多
暂无数据
了解AFMD最新的财务预测,通过AFMD每股收益,每股净资产,每股现金流等数据分析Affimed近期的经营情况,然后做出明智的投资选择。
分析师评级

9位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

33.33%强力推荐
66.67%买入
0.00%中性
0.00%落后大盘
0.00%卖出
目标价格预测
分析师预测AFMD价格均价为12.17,最高价位17.87,最低价为6.95。
最高17.87
均价12.17
最低6.95
现价3.280
EPS
实际EPS
预期EPS
-0.17-0.13-0.08-0.03
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Q1 2022
机构持股
总机构数: 150
机构持股: 9,041.80万
持股比例: 61.96%
总股本: 1.46亿
类型机构数股数
增持
35
1,094.89万
建仓
23
1,030.63万
减持
42
667.14万
平仓
24
470.33万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
生物技术和医学研究
+0.23%
制药与医学研究
+1.02%
高管信息
Chairman - Supervisory/Independent Director
Thomas Hecht
Chief Executive Officer/Management Board
Adi Hoess
Chief Financial Officer/Management Board
Angus Smith
Chief Operating Officer/Management Board
Wolfgang Fischer
Chief Scientific Officer/Management Board
Arndt Schottelius
Management Board
Andreas Harstrick
Management Board
Denise Mueller
Independent Director/Supervisory Board
Bernhard Ehmer
Independent Director/Supervisory Board
Ulrich Grau
Independent Director/Supervisory Board
Uta Kemmerich-Keil
Independent Director/Supervisory Board
Mathieu Simon
Independent Director/Supervisory Board
Harry Welten
Supervisory Board
Annalisa Jenkins
暂无数据
暂无数据
AFMD 简况
Affimed NV是一家临床阶段的生物制药公司,致力于发现和开发癌症免疫疗法。该公司开发免疫肿瘤领域的候选产品,代表一种旨在利用人体自身免疫系统对抗肿瘤细胞的癌症研究方法。其产品包括AFM13、AFM13+过继性NK细胞、AFM13+抗PD-1、AMF24、AMF26、AMF28和AMF32。该公司正在将患者纳入针对AFM13的CD30阳性复发/难治性外周T细胞淋巴瘤的定向研究,以及AFM24治疗晚期EGFR表达实体瘤的1/2a剂量递增/扩展研究。其临床前候选产品包括用于治疗多发性骨髓瘤的AMF26,以及用于治疗多个肿瘤靶标的AMF28和AMF32。此外,该公司与Genentech合作,开发和商业化可治疗多种癌症的候选产品。

微牛提供Affimed NV(NASDAQ-AFMD)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的AFMD股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易AFMD股票基本功能。